Alloy Carbon Steel Sheet,Structural Alloy Steel Plate,Alloy Steel Plate,Alloy Steel Sheet LIAOCHENG CHANGYI METAL MATERIAL CO., LTD. , https://www.cnsteelsheet.com
In 2014, the new GMP reform in the pharmaceutical industry started the GMP certification of aseptic pharmaceutical manufacturers in the year, which triggered a hot climax in the pharmaceutical industry. In 2014, only four city companies passed the certification, but this is not the end, except for sterile pharmaceutical manufacturers. In addition, the new version of GMP also stipulates that other pharmaceutical manufacturers must pass certification at the end of 2015, otherwise it will also be difficult to avoid production suspension.
For the remaining two-year transitional period, 2014 will surely become a large-scale new GMP reform start year related experts pointed out: Based on the experience of the first version of GMP certification, the earlier the company successfully passed certification, its The more advantage of sales bidding.
Even if companies that have not passed the new GMP certification have expanded their production before the expiration of the deadline, they can store several quarters of their products and maintain their supply for a period of time, making the sales of GMP-certified companies unlikely to burst in the short term.
However, from the flexibility of the pharmaceutical market in 2014, the obvious benefit will be the relatively low-end varieties in the field of injections. For example, the market concentration of antibiotic injections such as Cologne Pharmaceuticals, China Resources Double Crane, etc. will be higher. The speed will be gradually released, which is not bad for companies that have passed the new GMP certification.
Therefore, as long as there is a certain strength or ability of the company will implement the new version of GMP transformation as soon as possible, will not wait and see attitude in 2015 to apply for extension.
In addition, there are numerous pharmaceutical manufacturing enterprises in China, and the overproduction of pharmaceutical production capacity is relatively prominent. Taking a freeze-dried powder injection in a sterile pharmaceutical manufacturing company as an example, only 20% of companies that have passed the new GMP certification will be able to supply nearly 70% of the market demand. This fully illustrates the problems in the structure and production capacity of China's pharmaceutical industry. .
In 2014, as a large-scale new GMP reform startup year, relevant companies should learn lessons from the early stage. In the new year, other pharmaceutical manufacturers need to continuously strengthen technological transformation and strive to achieve certification as soon as possible.
After GMP certification: The pharmaceutical industry is in urgent need of seeking new development methods. After the GMP certification, although the number of domestic pharmaceutical companies has decreased, the quality, production capacity and level, and product quality have greatly improved, and the demand for pharmaceutical machinery has also increased. . The previous development methods have gradually shown its deficiencies, and the pharmaceutical machinery industry urgently needs to seek new development methods.
With the shift of demand from downstream pharmaceutical companies to high-end pharmaceutical machinery, the market demand for medium and low-end pharmaceutical machinery equipment has begun to stabilize. In addition, giants of foreign pharmaceutical machinery and equipment manufacturers have continued to infiltrate the Chinese medicine machine market, causing overcapacity in the domestic pharmaceutical machinery equipment manufacturing industry. The phenomenon has emerged. How to win the top spot and gain an opportunity in the fierce market competition is a question worthy of consideration by all pharmaceutical companies. For consumers, choose a brand with good user reputation, high quality and good service, or choose a product with only profitability and no emphasis on product quality and market maintenance? The answer is self-evident. This shows that pharmaceutical companies must pay attention to product brand building.
If pharmaceutical companies want to gain a place in market competition and obtain long-term support from customers, they must fully strengthen their product branding. Therefore, it is necessary for pharmaceutical machinery companies to actively carry out advertisements and marketing plans that are in line with the company’s actual needs in relation to brand building, and can enhance the brand’s drug use through product brand promotion meetings, marketing symposiums, large-scale advertisement billboards, and brochures. The familiarity in the enterprise increases the incremental effect of the product brand. In addition, the company must establish a scientific and rational product brand building system, integrate brand building, core corporate competitiveness and corporate culture construction, establish a long-term brand building mechanism, and continue to promote the brand building process.
In the fierce competition, domestic pharmaceutical companies should give full play to their advantages and strengthen their strength in pre-sale and after-sales services. Pharmaceutical companies should be good at seizing market opportunities for differentiation and increase their technological forces to research and develop equipment suitable for the manufacture of Chinese medicine.
Factors Restricting the Development of China's Pharmaceutical Machinery In recent years, the scale of domestic pharmaceutical machinery companies has developed rapidly, and technological progress has also been rapid. However, compared with foreign industries, the gap is still very large.
There are two main factors: First, industry development is related to the past environment. In the past, there was little support from the state, and the idea of ​​quick success for enterprises was serious, leading to heavy host and light components; Second, the domestic pharmaceutical machinery equipment industry has little research investment and weak foundation. .
Adjust and optimize the hardware industry structure and promote industrial upgrading The Chinese pharmaceutical machinery industry is a labor-intensive industry. In China's export products, labor-intensive products will still dominate for a long period of time. At the same time, it should be noted that for various reasons, the advantages of labor-intensive export products are slowly weakening.
For long-term development of Chinese pharmaceutical machinery equipment, it is necessary to adjust and optimize the industrial structure. It is necessary to continue to give full play to the advantages of traditional industries, but also to vigorously develop knowledge, technology-intensive industries and emerging industries in order to promote the upgrading of the industry. Only in this way can we shorten the gap between China's pharmaceutical machinery industry and developed countries as soon as possible.
Cultivating and Introducing Hardware Professionals to Improve Intellectual Capital Factors The current lack of professionals has become a bottleneck restricting the further development of the pharmaceutical equipment industry in China, which will inevitably affect the international competitiveness of our industry. To solve this problem, we can take the path of internal development and external introduction. On the one hand, short-term training for existing employees of the company can be strengthened to improve the existing human resources; on the other hand, talents of high-quality industries are introduced through various channels to increase the intellectual capital of the pharmaceutical machinery industry in China.
New Year of GMP Transformation Start-up: Strengthening of Technical Innovation in Pharmaceutical Machinery is Imperative
China's pharmaceutical machinery started in the 1980s. Throughout the past 30 years of development, the industry has the characteristics of a market cycle, that is, the development momentum of the pharmaceutical machine market is derived from the upgrading of the pharmaceutical industry. After 30 years of development, pharmaceutical machinery has gradually grown into an independent industry and is increasingly valued by all parties in society. As the country's medical investment continues to increase and the pharmaceutical market expands, the pharmaceutical machinery industry will continue to maintain rapid growth.